Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Linagliptin as a Multi-Target Neuroprotective Agent in Cognitive Disorders: Molecular Mechanisms and Translational Challenges-A Narrative Review.

Created on 16 Nov 2026

Authors

Leila Mohammadi, Mehrdad Roghani, Tourandokht Baluchnejadmojarad

Published in

Drug design, development and therapy. Volume 20. Pages 645071. Epub Nov 11, 2026.

Abstract

Cognitive disorders, which are characterized by progressive impairment of memory, language, and other cognitive functions, are a growing global health challenge. Currently, there are limited therapeutic options available to prevent or reverse the progression of these disorders. Linagliptin, an approved treatment for type 2 diabetes, has recently emerged as a neuroprotective agent, offering benefits beyond its glucose-lowering effects. Preclinical studies have demonstrated that linagliptin improves cognitive performance and protects neuronal integrity in various experimental models, including Alzheimer's disease (AD), Parkinson's disease (PD), cerebral ischemia, diabetic cognitive dysfunction, demyelination, and toxicant-induced cognitive impairment. The neuroprotective actions of linagliptin are mediated through multiple mechanisms, including the attenuation of endoplasmic reticulum (ER) stress, mitochondrial dysfunction, neuroinflammation, and oxidative stress, as well as the inhibition of apoptotic pathways, preservation of blood-brain barrier (BBB) integrity, and enhancement of neurovascular function. This multi-target profile highlights the potential of linagliptin as a promising therapeutic candidate for cognitive disorders. Despite encouraging preclinical findings, the CARMELINA and CAROLINA-COGNITION trials found no significant cognitive benefit of linagliptin, highlighting the gap between preclinical evidence and demonstrated clinical efficacy. This narrative review summarizes the molecular mechanisms and preclinical and clinical evidence regarding the effects of linagliptin in cognitive disorders, with particular emphasis on its potential neuroprotective mechanisms and translational challenges.

PMID:
43036638
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement